SAB Biotherapeutics (SABS) News
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.81-0.10 (-3.44%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SABS news summary
We found 4 recent headlines mentioning SAB Biotherapeutics (SABS): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire. For price context, SABS is down 3.44% at $2.81. The most recent story, "SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights", was published by GlobeNewswire on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest SAB Biotherapeutics headlines
- SAB BIO Reports Q3 2026 Financial Results and Provides Business HighlightsAdult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026GlobeNewswire
- SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ETMIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…GlobeNewswire
- SAB BIO to Participate in Chardan 10th Annual Healthcare ConferenceMIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…GlobeNewswire
- SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 DiabetesFast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetesGlobeNewswire